A Randomized, Placebo-controlled, Patient and Investigator Blinded, Single Dose, Proof of Concept Study Investigating the Safety, Tolerability and Preliminary Efficacy of Intra-articular LNA043 in Regenerating the Articular Cartilage of the Knee at Donor Sites in Patients Undergoing Autologous Chondrocyte Implantation
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2018
At a glance
- Drugs LNA 043 (Primary)
- Indications Cartilage disorders
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 17 Dec 2018 Planned End Date changed from 14 May 2019 to 31 Oct 2019.
- 17 Dec 2018 Planned primary completion date changed from 14 May 2019 to 30 Oct 2019.
- 26 Jul 2018 Planned End Date changed from 27 Nov 2018 to 14 May 2019.